Cargando…
Elosulfase alfa for mucopolysaccharidosis type IVA: Real-world experience in 7 patients from the Spanish Morquio-A early access program
There is a growing interest in evaluating the effectiveness of enzyme replacement therapy (ERT) with elosulfase alfa in patients with mucopolysaccharidosis type IVA (MPS-IVA) under real-world conditions. We present the experience of seven pediatric MPS-IVA patients from the Spanish Morquio-A Early A...
Autores principales: | Pintos-Morell, Guillem, Blasco-Alonso, Javier, Couce, María L., Gutiérrez-Solana, Luís G., Guillén-Navarro, Encarna, O'Callaghan, Mar, del Toro, Mireia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6047108/ https://www.ncbi.nlm.nih.gov/pubmed/30023300 http://dx.doi.org/10.1016/j.ymgmr.2018.03.009 |
Ejemplares similares
-
Role of elosulfase alfa in mucopolysaccharidosis IVA
por: Regier, Debra S, et al.
Publicado: (2016) -
Safety and clinical activity of elosulfase alfa in pediatric patients with Morquio A syndrome (mucopolysaccharidosis IVA) less than 5 y
por: Jones, Simon A., et al.
Publicado: (2015) -
Elosulfase alfa in the treatment of mucopolysaccharidosis type IVA: insights from the first managed access agreement
por: Stevens, Bob, et al.
Publicado: (2021) -
Efficacy of Intravenous Elosulfase Alfa for Mucopolysaccharidosis Type IVA: A Systematic Review and Meta-Analysis
por: Lee, Chung-Lin, et al.
Publicado: (2022) -
Clinical Utility of Elosulfase Alfa in the Treatment of Morquio A Syndrome
por: Lee, Chung-Lin, et al.
Publicado: (2022)